



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Mouse anti-Napsin, clone IP64 (monoclonal)

Clone no. IP64

MONXtra

---

Product name	Mouse anti-Napsin, clone IP64 (monoclonal)
Host	Mouse
Applications	IHC-P (1:400)
Species reactivity	human
Conjugate	-
Immunogen	Prokaryotic recombinant protein corresponding to 126 amino acids of the Napsin A protein.
Isotype	IgG2b
Clonality	Monoclonal
Clone number	IP64
Size	1 ml
Concentration	Greater than or equal to 8.3 mg/L
Format	-
Storage buffer	Tissue culture supernatant with sodium azide
Storage until expiry date	2-8°C

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES

Mouse anti-Napsin, clone IP64 (monoclonal)

Clone no. IP64

MONXtra

---

**Additional info**

Napsin A has a specific function in normal alveolar epithelium and is proposed to play a role in the proteolytic processing of surfactant precursors. Napsin A is reported to be predominantly expressed in lamellar bodies of type II pneumocytes, secondary lysosomes of alveolar macrophages, respiratory epithelium of terminal and respiratory bronchioles, plasma cells, within a subset of lymphocytes in normal lung, as well as in epithelial cells of renal tubules in normal kidney and is weakly expressed in normal spleen. Studies have reported that Napsin A is expressed in 90% of primary lung adenocarcinomas.

**References**

1. Yamashita Y et al. Modern Pathology. 2015; 28: 111-11
2. Kandalajt PL et al. American Journal of Clinical Pathology. 2014; 142: 830-836
3. Bishop JA et al. Human Pathology. 2010; 41: 20-25
4. Chuman YC et al. FEBS Letters 1999; 462, 129-134
5. Tatnell PJ et al. FEBS Letters 1998; 441, 43-48

**FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES**